Pictured: William Tap
MSK at ASCO
By Media Staff  |  Thursday, May 15, 2014

New Memorial Sloan Kettering research demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of a rare and debilitating joint disease.

Pictured: Renier Brentjens, Isabelle Rivière & Michel Sadelain
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, February 20, 2014

A new study evaluating a cell-based immune therapy to treat an aggressive type of leukemia — the largest study of its kind to date — reports that 88 percent of patients responded to the treatment.

Pictured: Diane Reidy
Feature
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, February 19, 2014

Cycle for Survival, Memorial Sloan Kettering’s nationwide indoor team cycling event, helps support research into rare cancers. Three researchers discuss how these funds benefit their research.

Pictured: Oliver Zivanovic, Garrett Nash & Dennis Chi
In the Clinic
By Esther Napolitano, BS, Science Writer/Editor  |  Friday, November 15, 2013

Memorial Sloan Kettering experts are leading investigations of a procedure called hyperthermic intraperitoneal chemotherapy, also known as HIPEC.

Pictured: Anas Younes, Chief, Lymphoma Service
Profile
By Jim Stallard, MA, Writer/Editor  |  Wednesday, October 30, 2013

Medical oncologist Anas Younes leads an ambitious effort to find disease biomarkers that could predict which lymphoma patients will benefit from new targeted therapies.

Perspective
By Paul Sabbatini, MD, Deputy Physician-in-Chief for Clinical Research  |  Friday, July 26, 2013

The clinical trial remains our best tool to identify new therapies, but as with all tools, innovation is required if trials are to remain relevant.

Pictured: Jedd Wolchok & Richard Carvajal
In the Clinic
By Media Staff  |  Monday, June 3, 2013

Two Memorial Sloan Kettering studies that hold promise for the treatment of advanced uveal (eye) melanoma and advanced skin melanoma are making headlines at the 49th Annual Meeting of the American Society of Clinical Oncology.

Pictured: Robert Motzer & Suzanne Gornell
Video
By Allyson Collins, MS, Science Writer/Editor  |  Wednesday, May 8, 2013

Our experts have participated in or led the development of five of the seven drugs approved by the US Food and Drug Administration for patients with advanced kidney cancer since 2005.

Pictured: Gary Schwartz & Mark Dickson
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Monday, April 22, 2013

Two clinical trials of targeted therapies led by Memorial Sloan Kettering investigators show promising results against different types of sarcoma.

Pictured: José Baselga
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Monday, April 8, 2013

Memorial Sloan Kettering’s Physician-in-Chief, José Baselga, explains the findings from three studies on new targeted therapies for breast cancer.

Pictured: Jedd Wolchok
In the Clinic
By Media Staff  |  Thursday, April 4, 2013

Early research led by investigators at Memorial Sloan Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Pictured: Paul Sabbatini
Q&A
By Media Staff  |  Tuesday, April 2, 2013

In his new role as Deputy Physician-in-Chief for Clinical Research, Paul Sabbatini aims to streamline, accelerate, and expand Memorial Sloan Kettering’s clinical research program.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Wednesday, March 20, 2013

Memorial Sloan Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

Pictured: Robin Roberts & Tonya Samuel
In the News
By Jim Stallard, MA, Writer/Editor  |  Wednesday, February 20, 2013

Co-host Robin Roberts gives thanks to her Memorial Sloan Kettering treatment team during her first day returning to the show after receiving a stem cell transplant.

Pictured: James Fagin
In the Clinic
By Media Staff  |  Thursday, February 14, 2013

Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.

Center News

Stay Informed

Get the latest information about cancer care and research every month.